Royalty Pharma (RPRX) director granted 815-share equity award

Rhea-AI Filing Summary

Bassler Bonnie L reported acquisition or exercise transactions in this Form 4 filing.

Royalty Pharma plc director Bonnie L. Bassler received an equity grant of 815 Class A Ordinary Shares. The award was made on a grant/award basis at a reference price of $45.977 per share and was issued under the company’s 2020 Independent Director Equity Incentive Plan in lieu of a $37,500 quarterly retainer payment. Following this grant, Bassler directly holds 73,947 Class A Ordinary Shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bassler Bonnie L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	815	$45.977	$37K

Holdings After Transaction: Class A Ordinary Shares — 73,947 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 815 shares Grant price per share: $45.977/share Retainer value: $37,500 +1 more

4 metrics

Shares granted 815 shares Class A Ordinary Shares granted as director compensation

Grant price per share $45.977/share Reference price for the 815-share equity award

Retainer value $37,500 Quarterly retainer replaced by share grant

Shares owned after grant 73,947 shares Class A Ordinary Shares directly held by Bonnie L. Bassler after transaction

Key Terms

Class A Ordinary Shares, 2020 Independent Director Equity Incentive Plan, quarterly retainer payment, grant, award, or other acquisition

4 terms

Class A Ordinary Shares financial

"Reflects Class A Ordinary Shares issued to the reporting person"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

2020 Independent Director Equity Incentive Plan financial

"issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan"

quarterly retainer payment financial

"in lieu of a quarterly retainer payment of $37,500"

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bassler Bonnie L

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NEW YORK 10022

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	03/31/2026		A		815	A	$45.977(1)	73,947	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.

Remarks:

	/s/ Sean Weisberg, as Attorney-in-Fact for Bonnie L. Bassler	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did director Bonnie L. Bassler report in the Royalty Pharma (RPRX) Form 4?

Bonnie L. Bassler reported receiving 815 Class A Ordinary Shares of Royalty Pharma as an equity grant. The shares were issued as compensation under the 2020 Independent Director Equity Incentive Plan in lieu of a cash quarterly retainer payment of $37,500.

How many Royalty Pharma (RPRX) shares did Bonnie L. Bassler receive and at what price?

Bonnie L. Bassler received 815 Class A Ordinary Shares at a reference price of $45.977 per share. This award reflects a grant or other acquisition transaction, rather than an open-market purchase or sale, as part of her director compensation package.

What was the cash value replaced by shares in this Royalty Pharma (RPRX) Form 4?

The equity grant replaced a quarterly retainer payment of $37,500. Instead of receiving this amount in cash, Bonnie L. Bassler was issued 815 Class A Ordinary Shares under the 2020 Independent Director Equity Incentive Plan as part of her compensation.

How many Royalty Pharma (RPRX) shares does Bonnie L. Bassler own after this grant?

After the reported grant, Bonnie L. Bassler directly owns 73,947 Class A Ordinary Shares of Royalty Pharma. This figure reflects her holdings following the issuance of 815 additional shares as equity compensation in lieu of a quarterly cash retainer.

Was the Royalty Pharma (RPRX) Form 4 transaction a market purchase or sale?

The transaction was not a market purchase or sale; it was a grant or award acquisition. The 815 Class A Ordinary Shares were issued as compensation under the 2020 Independent Director Equity Incentive Plan instead of paying a $37,500 quarterly retainer in cash.